My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

COMPLETED

Identifier: CI-TRIAL-00079050
Entity page: /trial/NCT02091141 ↗
Edges: 11

Neighbours: 3 cancers8 drugs
Drawn: 11 of 11 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors condition of …CONDITION_OFderived3 of 3
← condition of	Malignant Bladder Neoplasm registry condition “Bladder Cancer” mapped CURATED_EXACT	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Neoplasm registry condition “Neoplasms” mapped ONTOLOGY_EXACT

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors intervention of …INTERVENTION_OFderived8 of 8
← intervention of	Alectinibsmall molecule registry intervention “Alectinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Atezolizumabmonoclonal antibody registry intervention “Atezolizumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cobimetinibsmall molecule registry intervention “Cobimetinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Erlotinibsmall molecule registry intervention “Erlotinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pertuzumabmonoclonal antibody registry intervention “Pertuzumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Trastuzumabmonoclonal antibody registry intervention “Trastuzumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Vemurafenibsmall molecule registry intervention “Vemurafenib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Vismodegibsmall molecule registry intervention “Vismodegib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors intervention of …INTERVENTION_OFderived8 of 8

← intervention of

Alectinibsmall molecule

registry intervention “Alectinib” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Atezolizumabmonoclonal antibody

registry intervention “Atezolizumab” (DRUG) mapped ALIAS

—